Pharmaceuticals frequently make people feel "stoned." Sativix is not aspirin or ibuprofen. It is a depressant like codeine, morphine, sleeping pills, all of which have depressive effects. Doctors prescribe pharmaceuticals knowing that the negatives of the side effects, no matter what they are, are outweighed by the benefits of the drug. That's the call a prescribing doctor makes. In this case, it's better for a patient to feel drowsy than to be tormented by uncontrollable seizures. It's a balancing act. This stock will fly once FDA approved. It's the government's only alternative to the sham of "medical" mj. It will be in their wheel house, regulated and controlled. Doctors likewise do not want to prescribe joints and patients do not want to smoke their medicine.
As one dumb American who is overpaid, over fed, over sexed and over here, I can tell you that the DEA, Customs and Border Patrol, FDA and WHouse would LOVE to have an approved pharmaceutical to defeat or at least slow the current trend of the proliferation of pot. Likewise the medical profession prefers to prescribe pills over joints. Patients prefer to swallow prescribed FDA approved meds over smoking them. And states like mine that are tired of propping up the sham of "medical MJ" for outright recreational use would love to recover the rule of law. GW is leading the realization of this vision. My stake is big and I sleep comfortably.
Sentiment: Strong Buy
GW is a different business from mmj. The masses want to take their medicine in pills, not smoke. Doctors want to prescribe pills, not joints. GW legitimized and mainstreams mmj in a way that smoke shops and cooperatives never will. Get a clue. GW is the vanguard of formally prescribed mmj derivatives that doctors and anti-dopers will be using henceforth and that governments will comfortably approve
Sentiment: Strong Buy
Taking taxable capital gains in this year because next year they will be HUGE. Same happening elsewhere in my high runup portfolio. This is a volatile small cap with great fundamentals. At this price level likely more institutions upping the ante in a month or so. Just hold on. Sell high if you must.